Atypical B cells and impaired SARS-CoV-2 neutralization following heterologous vaccination in the elderly

Basic information
Cell
99,384
Sample
39

Technology
10X Genomics
Omics
scRNA-seq
Source
PBMCs

Dataset ID
37590132
Platform
Illumina NovaSeq 6000
Species
Human
Disease
Healthy/vaccine
Age range
52 - 75
Update date
2023-08-29
Summary

Suboptimal responses to a primary vaccination course have been reported in the elderly, but there is little information regarding the impact of age on responses to booster third doses. Here, we show that individuals 70 years or older (median age 73, range 70–75) who received a primary two-dose schedule with AZD1222 and booster third dose with mRNA vaccine achieve significantly lower neutralizing antibody responses against SARS-CoV-2 spike pseudotyped virus compared with those younger than 70 (median age 66, range 54–69) at 1 month post booster. Impaired neutralization potency and breadth post third dose in the elderly is associated with circulating “atypical” spike-specific B cells expressing CD11c and FCRL5. However, when considering individuals who received three doses of mRNA vaccine, we did not observe differences in neutralization or enrichment in atypical B cells. This work highlights the finding that AdV and mRNA COVID-19 vaccine formats differentially instruct the memory B cell response.

Overall design

This data includes scRNA-seq, scTCR-seq and scBCR-seq of 21 individuals post Covid'19 vaccination. Individuals range from the ages 52 to 75. Samples were genotype multiplexed in an overlapping mixture design, pooled, and sequenced on 16 lanes (10X, 5' GEM).

Contributors

To be supplemented.

Contact

To be supplemented.

snRNA-Seq
Sample nameSample titleDiseaseGenderAgeSourceTreatmentTechnologyPlatformOmicsSample IDDataset IDAction
No data available